|Bid||90.00 x 1400|
|Ask||0.00 x 900|
|Day's Range||101.59 - 102.86|
|52 Week Range||69.59 - 104.78|
|PE Ratio (TTM)||51.70|
|Forward Dividend & Yield||1.40 (1.44%)|
|1y Target Est||N/A|
At the Berkshire Hathaway annual shareholder meeting, Warren Buffett and Charlie Munger discuss health care and finding a better way to provide it.
ResMed (RMD) presents the company-sponsored health economic studies, Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV), at the ATS 2018 International Conference.
Companies like Broadcom Ltd. and Norwegian Cruise Line Holdings Ltd. are adding back millions in “ghost revenue” — deferred revenue that accounting standards force them to write off after an acquisition — when calculating executive bonuses, an issue that is taking on new resonance after a former Symantec Corp. employee complained about the practice internally and prompted an audit committee investigation.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
There are a number of reasons that attract investors towards large-cap companies such as ResMed Inc (NYSE:RMD), with a market cap of US$13.95B. Market participants who are conscious of riskRead More...
The San Diego-based company said it had net income of 76 cents per share. Earnings, adjusted for amortization costs and restructuring costs, came to 92 cents per share. The results beat Wall Street expectations. ...
Integra LifeSciences' (IART) revenue growth was primarily driven by high organic revenues, successful progress with Codman integration and progress with the channel expansion strategy.
LabCorp's (LH) Diagnostics business was solid on the back of increasing acquisitions, organic volume expansion and a favorable foreign exchange scenario.
Thermo Fisher's (TMO) performance in Q1 benefits from a series of product launches alongside a major progress in precision medicine initiatives.
Let's take a look at the factors that are likely to impact the earnings results of a few MedTech bigwigs within the broader Medical universe.
ResMed's (RMD) sleep apnea patient volume consistently witnesses a steady expansion. We expect this upside to continue in the fiscal third quarter as well.
ResMed (RMD) continues to benefit from solid sales of sleep devices, respiratory care devices, mask systems and software solutions globally.
ResMed (RMD) boosts investor confidence on strength in Software-as-a-Service businesses as well as new mask products and devices.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding RMD totaled $1.87 billion.
ResMed (RMD) consistently invests and expands globally in high-growth markets like China, South Korea, India, Brazil and across the Eastern Europe belt.
ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.